16 September 2026
16 September 2026
QurCan will optimise genetic therapeutics using its technology, with Lilly overseeing further research and commercialisation.
Electra likens its targeted approach in immune-mediated disease to what precision oncology has achieved in cancer.
The collaboration enables 14 countries to access lenacapavir for PrEP outside of Gilead’s current voluntary licensing agreements.
As healthcare providers begin to embed agentic AI into their workflows, effective governance and multi-disciplinary accountability becomes key.
For the purpose of this single-centre observational study, 82 patients who were prospectively treated with biologics were included.
GSK plans to take the TCE to Phase I clinical trials in multiple myeloma during 2027.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
